AzTrials
AzTrials

PFIC - Progressive Familial Intrahepatic CholestasisREGENICNCT07191704

A Study to Assess the Genetic Variations in Bile Flow Disorders: Linking Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes to Symptoms in Adults With Recurrent Cholestasis in Spain

An observational study of PFIC - Progressive Familial Intrahepatic Cholestasis, run by Ipsen at 10 sites in Spain.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of inherited conditions that affect how bile moves in the liver, which can lead to serious liver problems. Doctors usually recommend genetic testing for patients with unexplained bile issues-after ruling out more common causes-to better understand the… Read more about this study

Who is it for?
Ages 18 years and older
How many people
150 participants
Where
10 sitesSpain
Study dates
8 Dec 2025to 3 Jun 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: 150 patients, both male and female, of age (≥ 18 years) with unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis) will be recruited

Who may be able to join

  • Adult patients (≥18 years old) with written informed consent prior to data collection and study procedures.
  • Unexplained recurrent and/or chronic cholestasis (idiopathic cholestasis), defined as alkaline phosphatase (ALP) or Gamma-Glutamyl Transferase (GGT) > Upper Limit of Normal (ULN).
  • Patients who provide the blood sample for the genetic analysis.

Who cannot join

  • Patients with clear and confirmed diagnosed causes of cholestasis, including:
  • Primary Biliary Cholangitis
  • Primary or Secondary Sclerosing Cholangitis
  • Obstruction of the bile ducts
  • Other Liver diseases: cholestasis secondary to hepatocellular injury, viral hepatitis (mainly Hepatitis A virus [HAV], Hepatitis B virus [HBV] and Hepatitis C virus [HCV]), toxic hepatitis (pharmacological; drug-induced liver injury [DILI]), autoimmune hepatitis; intestinal failure, total parenteral nutrition [TPN]; Wilson's disease, choledochal cyst, Caroli Syndrome, and thick bile due to haemolysis.

Trial locations and contacts

10 sites in 1 country.

10 sites in 1 country

Spain10 sites
  • H. Clinic (first CEIm)

    Barcelona

  • H. Vall Hebron

    Barcelona

  • H. Reina Sofía

    Córdoba

  • H. Dr. Negrín

    Las Palmas

  • H. Gregorio Marañón

    Madrid

  • Hospital Universitario La Paz

    Madrid

  • H. Virgen del Rocío

    Seville

  • H. La Fe

    Valencia

  • H. Río Hortega

    Valladolid

  • H. Miguel Servet

    Zaragoza

Other trials in Spain

About this study

Official title: Characterization of Progressive Familial Intrahepatic Cholestasis (PFIC)-Related Genes in Adult Patients With Idiopathic Recurrent and Chronic Cholestasis in Spain - REGENIC

Progressive Familial Intrahepatic Cholestasis (PFIC) is a group of inherited conditions that affect how bile moves in the liver, which can lead to serious liver problems. Doctors usually recommend genetic testing for patients with unexplained bile issues-after ruling out more common causes-to better understand the problem. However, there isn't much information on how common these genetic changes are in adults with these liver issues, especially in Spain. This study will observe these genetic changes so that doctors can diagnose the condition more clearly and create personalized treatment plans.

This study will be conducted in several centers across Spain for 10 months. Each adult participant will take part in a single-day visit where their health information will be collected, and a blood sample will be taken for both routine tests and genetic analysis.

Keywords
Cholestasis
Medical subject headings
Cholestasis, progressive familial intrahepatic 1, Cholestasis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants with at least One Variant in PFIC-Related Genes

    Defined as the percentage of participants with at least one variant in PFIC-related genes in relation to the total number of participants with idiopathic recurrent and/or chronic cholestasis of the study cohort as an assessment of prevalence.

    Measured: At enrollment

Secondary outcomes (30)
  1. Percentage of Participants Carrying Each Identified Variant of Genes related to PFIC

    Defined as the percentage of participants carrying each identified variant of genes related to PFIC.

    Measured: At enrollment

  2. Demographic Data: Age at Enrollment

    Defined as the mean age of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  3. Demographic Data: Sex at Enrollment

    Defined as the count of sex of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  4. Demographic Data: Race/Ethnicity at Enrollment

    Defined as the race/ethnicity of participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  5. Demographic Data: Weight at Enrollment

    Defined as the mean weight participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  6. Demographic Data: Height at Enrollment

    Defined as the mean height participants recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  7. Demographic Data: Body Mass Index (BMI) at Enrollment

    Defined as the mean BMI, calculated by dividing participant's weight in kilograms by the square of their height in meters (BMI = weight ÷ height²), as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  8. Demographic Data: Alcohol Consumption at Enrollment

    Defined as the mean of standard drinks in a week to assess the alcohol consumption, recorded at the time of enrollment, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  9. Age at Cholestasis Diagnosis

    Defined as the mean participant's age when first symptoms were reported, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  10. History of Liver Disease

    Defined as the count of presence of liver conditions such as gallstones, pancreatitis, and cirrhosis (among other relevant conditions), as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  11. History of Diagnostic Procedures Used

    Defined as the count of presence of diagnostic procedures performed, including liver biopsy and elastography (Fibroscan) as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  12. Presence of Liver Disease Symptoms

    Defined as the count of presence of liver condition symptoms such as jaundice, pruritus and disease-related fatigue, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  13. History of liver or biliary disease related surgeries

    Defined as the count of history of liver or biliary disease related surgeries, such as cholecystectomy, liver transplantation, surgical biliary diversion (SBD) or other liver-related surgery, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  14. Family history of liver disease

    Defined as the count of family history of liver disease, such as the presence or absence of PFIC, intrahepatic cholestasis of pregnancy (ICP), benign recurrent intrahepatic cholestasis (BRIC), low-phospholipid-associated cholelithiasis (LPAC), portal hypertension, hepatocellular carcinoma, cholangiocarcinoma, pancreatitis, gallstones, cirrhosis, cholestatic drug induced liver injury (DILI), Metabolic dysfunction-associated fatty liver disease (MASLD), Non-alcoholic Steatohepatitis (MASH) and any other chronic liver disease, and which close relative has suffered it (parent, grandparent, sibling, etc.), as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  15. Presence or Absence of Fat-Soluble Vitamin deficiencies

    Defined as the count of presence or absence of vitamin deficiencies, such as vitamin A, D, E and K and supplementation, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  16. Laboratory Analysis of Haematology - Haemoglobin

    Defined as the last recorded routine analysis of haemoglobin, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  17. Laboratory Analysis of Haematology - Red Blood Cell (RBC) count

    Defined as the last recorded routine analysis of RBC count, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  18. Laboratory Analysis of Haematology - Leukocytes

    Defined as the last recorded routine analysis of leukocytes, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  19. Laboratory Analysis of Haematology - Platelets

    Defined as the last recorded routine analysis of platelets, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  20. Laboratory Analysis of Chemistry - Alanine aminotransferase (ALT)

    Defined as the recorded routine analysis of ALT, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  21. Laboratory Analysis of Chemistry - Aspartate aminotransferase (AST)

    Defined as the recorded routine analysis of AST, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  22. Laboratory Analysis of Chemistry - Alkaline Phosphatase (ALP)

    Defined as the recorded routine analysis of ALP, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  23. Laboratory Analysis of Chemistry - Total and direct bilirubin

    Defined as the recorded routine analysis of total and direct bilirubin, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  24. Laboratory Analysis of Chemistry - Bile Acids (sBA)

    Defined as the recorded routine analysis of sBA, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  25. Laboratory Analysis of Chemistry - Gamma-Glutamyl Transferase (GGT)

    Defined as the recorded routine analysis of GGT, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  26. Laboratory Analysis of Chemistry - Albumin

    Defined as the recorded routine analysis of albumin, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  27. Laboratory Analysis of Coagulation - Prothrombin time

    Defined as the recorded routine analysis of prothrombin time, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  28. Laboratory Analysis of Coagulation - International Normalized Ratio (INR)

    Defined as the recorded routine analysis of INR, as noted in medical records, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  29. Frequency of Prior and Concomitant treatment for cholestatic liver disease and pruritus.

    Defined as the count of prior and concomitant treatment for cholestatic liver disease and pruritus: ursodeoxycholic acid (UDCA), cholestyramine, rifampicin, fibrates, ileal bile acid transporter inhibitors (IBATi), selective serotonin reuptake inhibitors (SSRI), opioid antagonists, Chaperones (4- phenylbutyrate, [4-PB]) skin emollients or others, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

  30. Comorbidities of interest (i.e., diabetes, metabolic syndrome, osteopenia/osteoporosis)

    Defined as the count of comorbidities of interest, such as diabetes, metabolic syndrome, osteopenia/osteoporosis, as noted in medical records or participant recollection, stratified by the PFIC type - comparing those with the most prevalent PFIC variant against all other participants.

    Measured: At enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Sep 2025
  2. Study start8 Dec 2025
  3. Primary completion3 Jun 2026
  4. Study completion3 Jun 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
150 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07191704
Sponsor's protocol ID
CLIN-60240-453
Acronym
REGENIC
Status last verified
Jul 2026
First submitted
17 Sep 2025
Last updated
3 Aug 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Questions about this trial

What is this clinical trial studying?

An observational study of PFIC - Progressive Familial Intrahepatic Cholestasis, run by Ipsen at 10 sites in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants with at least One Variant in PFIC-Related Genes (time frame: At enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Aug 2026; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in